Sales from the United States contributed more than 38 billion U.S. dollars towards Pfizer's total revenue of around 63.6 billion U.S. dollars in 2023. Pfizer sees strong growth in emerging markets Pfizer’s total revenue is divided into four geographic areas: the United States, Developed Markets, and Emerging Markets. China is one of the company’s largest single markets behind the United States, which contributed 60 percent of Pfizer’s total revenue. Pfizer continues to support investment in emerging markets, but the vulnerable nature of these countries means strategies come with an element of risk due to unforeseen financial or political events, for example. The power of product patents Managing the expiration of key patents is one of the greatest challenges facing Pfizer because competition from generic versions can make a big difference to company revenues. Many of Pfizer’s leading products enjoy the security of market exclusivity, but less expensive generic versions are free to enter the market when these property rights end. In 2019, Pfizer anticipated a fall in sales revenue from China due to significant competition from generic versions.

In fiscal year 2024, Pfizer's revenue by geographical region are as follows: Developed Rest Of World: $16.06 B, Emerging Markets: $8.88 B, UNITED STATES: $38.69 B.

Revenues generated from outside the United States accounted for almost two thirds of Pfizer's total revenue in 2024. During that year, the company generated revenues of roughly ** billion U.S. dollars in countries outside the United States. China emerges as an important market Pfizer sells its pharmaceutical products in more than *** countries worldwide, with the United States, China, and Japan being among the major national markets. In 2024, the United States alone contributed a share of more than ** percent. In terms of geographic area, emerging markets – which include China – generated revenues of approximately *** billion U.S. dollars in 2024. Analyzing Pfizer’s global operations In 2024, Pfizer had approximately 81,000 employees worldwide. The American company had ** manufacturing sites in countries ranging from Belgium to Singapore, each producing products that serviced the company’s commercial division. Pfizer also had several facilities that focused on research and development projects, many of which were located in North America.

Pfizer is a global pharmaceutical company and among the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2024, the company's total revenue stood at **** billion U.S. dollars. Pfizer’s global positioning Pfizer’s products are available in many countries worldwide and as of 2024, the company had more than *** research and development projects in the pipeline. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the leading pharmaceutical companies based on research and development (R&D) spending. Pfizer’s largest segment is Innovative Health (IH). The Innovative Health business focuses on various rare diseases, vaccines, immunology and internal medicine to name a few. Pfizer’s top products In 2024, products from the Prevnar family were among Pfizer's top products based on revenue. However, Pfizer has several other drugs that are also well-known. For example, Lipitor (atorvastatin calcium) is used in the treatment of high cholesterol. Over the years, however, Lipitor revenues have been on the decline due to patent loss, yet it remains part of Pfizer’s top products. One of Pfizer’s most well-known products, Viagra (sildenafil citrate), used in the treatment of erectile disfunction, has also been on the decline with 2019 having the lowest revenues on record. The low revenues are mainly attributable to Viagra’s loss of patent exclusivity in the U.S. in December 2017.

In fiscal year 2024, Pfizer's revenue by segment (products & services) are as follows: Biopharma Segment: $62.40 B.

As of **************, high-income countries accounted for around ** percent of total Pfizer/BioNTech vaccines delivered worldwide. The statistic illustrates the share of Pfizer/BioNTech COVID-19 vaccines delivered worldwide as of **************, by country income group.

United States US: PFE: Revenue (External): Essential Health Product: International: Developed Rest of World data was reported at 2,123,000.000 USD th in Sep 2018. This records an increase from the previous number of 1,402,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Developed Rest of World data is updated quarterly, averaging 1,878,000.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 3,343,000.000 USD th in Dec 2016 and a record low of 648,000.000 USD th in Mar 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Developed Rest of World data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data was reported at 2,394,000.000 USD th in Jun 2018. This records an increase from the previous number of 1,158,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data is updated quarterly, averaging 2,571,000.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 4,381,000.000 USD th in Dec 2017 and a record low of 872,000.000 USD th in Mar 2016. United States US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data was reported at 2,340,000.000 USD th in Sep 2018. This records an increase from the previous number of 1,591,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data is updated quarterly, averaging 2,277,000.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 4,442,000.000 USD th in Dec 2015 and a record low of 778,000.000 USD th in Mar 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Snapshot img { margin: 10px !important; }

The global conjugate vaccines market size has the potential to grow by USD 7.27 billion during 2020-2024. The market’s growth momentum will accelerate throughout the forecast period because of the steady increase in year-over-year growth.

This report provides a detailed analysis of the market by type (multivalent conjugate vaccine and monovalent conjugate vaccine) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including Aurobindo Pharma Ltd., GlaxoSmithKline Plc, Integrated Biotherapeutics Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Pfenex Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.

Market Overview

Browse TOC and LoE with selected illustrations and example pages of conjugate vaccines market

Request a FREE sample now!

Market Competitive Analysis

The conjugate vaccines market is currently moderately fragmented. The degree of fragmentation will increase slightly over the forecast period. With significant business growth scope in the market, vendors are focusing on R&D to release novel conjugate vaccines, which will increase their market penetration and revenue generation. Pfenex Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., and Sun Pharmaceutical Industries Ltd. are a few of the significant market participants. Although the awareness about immunization programs, and access to vaccines will offer immense business opportunities to vendors, the high cost associated with vaccine research, development, and manufacturing will challenge the growth of many. To make the most of the possibilities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

To help clients improve their market positions, this conjugate vaccines market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of the companies. The report also covers details on the market’s competitive landscape and provides information on the products offered by various companies. This conjugate vaccines market analysis report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of their future growth opportunities.

This report provides information on the production, sustainability, and prospects of several leading conjugate vaccines companies, including:

• Aurobindo Pharma Ltd.
• GlaxoSmithKline Plc
• Integrated Biotherapeutics, Inc.
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corp.
• Pfenex Inc.
• Pfizer Inc.
• Sanofi
• Serum Institute of India Pvt. Ltd.
• <span style="background:wh

United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data was reported at 1,753,000.000 USD th in Jun 2018. This records an increase from the previous number of 812,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data is updated quarterly, averaging 1,980,000.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 3,433,000.000 USD th in Dec 2017 and a record low of 707,000.000 USD th in Mar 2015. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

This statistic displays the leading 10 global vaccine products based on their revenues worldwide in 2023. Pfizer's COVID-19 vaccine Comirnaty generated nearly **** billion U.S. dollars in revenues in that year. Top vaccine products Vaccines act as a preventive measure to improve immunity to certain diseases. Often, vaccines are created from a weakened or killed form of a microbe which allows the immune system to react and create a record of it, so that in the future, it can easily recognize these microorganisms. Vaccine use can easily help to prevent contraction of certain viruses such as influenza. However, some countries may not have easy access to vaccinations. The global vaccination market is projected to reach around ** billion U.S. dollars in 2029. In 2023, Comirnaty and Gardasil were the top revenue generating vaccines in the world, generating **** billion and **** billion U.S. dollars, respectively. Comirnaty is marketed by Pfizer and BioNTech, while Gardasil is marketed by Merck & Co.

United States US: PFE: Revenue (External): Essential Health Product: International data was reported at 10,238,000.000 USD th in Sep 2018. This records an increase from the previous number of 6,891,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: International data is updated quarterly, averaging 8,591,500.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 14,836,000.000 USD th in Dec 2015 and a record low of 3,220,000.000 USD th in Mar 2017. United States US: PFE: Revenue (External): Essential Health Product: International data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data was reported at 2,835,000.000 USD th in Jun 2018. This records an increase from the previous number of 1,314,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data is updated quarterly, averaging 3,304,000.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 5,806,000.000 USD th in Dec 2014 and a record low of 1,174,000.000 USD th in Mar 2015. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Essential Health Product: International: Emerging markets data was reported at 5,775,000.000 USD th in Sep 2018. This records an increase from the previous number of 3,898,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Emerging markets data is updated quarterly, averaging 4,431,500.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 7,116,000.000 USD th in Dec 2015 and a record low of 1,610,000.000 USD th in Mar 2016. United States US: PFE: Revenue (External): Essential Health Product: International: Emerging markets data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Innovative Health Product: US data was reported at 9,121,000.000 USD th in Jun 2018. This records an increase from the previous number of 4,544,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: US data is updated quarterly, averaging 9,025,500.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 18,460,000.000 USD th in Dec 2017 and a record low of 2,972,000.000 USD th in Mar 2015. United States US: PFE: Revenue (External): Innovative Health Product: US data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Demand for Active Pharmaceutical Ingredients (APIs) and other pharmaceutical substances produced by the Basic Pharmaceutical Product Manufacturing industry depends on consumer demand for pharmaceutical products. Over the past few years, an ageing Irish population has bolstered demand for pharmaceutical products, as pharmaceutical treatments for degenerative illnesses have become more popular. Rising obesity levels and associated health conditions, like diabetes, have also lifted demand for pharmaceuticals. Industry revenue is anticipated to climb at a compound annual rate of 5.9% over the five years through 2024, including a forecast growth of 2.9% in 2024, to reach €16.7 billion. Over the two years through 2021, pharmaceutical product manufacturers' demand benefitted from the COVID-19 outbreak, as APIs were used in COVID-19 vaccine trials and antibody tests collected using blood sampling. Although revenue from COVID-19-related products is in sharp decline in 2024, the high diversification of the industry means industry revenue will continue to grow regardless. Low corporate tax rates have made the country an attractive location for global pharmaceutical manufacturers. Nine of the 10 largest pharmaceutical companies in the world have a presence in the country, making Ireland the world's third largest exporter of pharmaceuticals, according to the UN International Trade Statistics database. Most industry manufacturers are dependent on exports for revenue growth. The industry's global nature has created fierce domestic and export market competition. Low-cost manufacturers in developing countries are often able to outprice domestic producers, so ongoing innovation and product development have been key to ensuring consistent growth over recent years. The continued expanding and ageing Irish population, as well as more establishments being opened in Ireland, will be the driving forces behind industry expansion over the coming years. Industry revenue will rise at a compound annual rate of 6.4% over the five years through 2029, reaching €22.8 billion. Innovation and rapid product development will be crucial to success for new entrants and incumbents, including drugs for age-related illnesses, obesity and effective antibiotics to tackle growing resistance levels. More efficient manufacturing from the wider use of new technologies will also support profit growth.

In 2017, the United States, followed by (the leading 15 countries from) Western Europe, had that largest share of pharmaceutical revenue globally. For comparison, Australia had one of the lowest single shares among the listed countries. The data shows that the United States held 33 percent of global pharmaceutical revenue. The pharmaceutical industry is composed of various actors responsible for the discovery, development, and distribution of drugs and medicines.

The global pharma industry

The worldwide pharmaceutical market was recently valued at over 1.14 trillion U.S. dollars. Trends suggest that the pharmaceutical market globally is on the increase. In recent years Pfizer had the largest amount of global prescription sales; however, Roche had the highest research and development spending. Research and development is important for creating new, innovative pharmaceuticals, since branded products are under the threat of patent expiration and generic competition after a certain amount of years.

Leading therapeutic classes

Based on therapeutic classes, at this moment, the largest shares of pharmaceuticals sales globally are attributable to oncologics and pain management drugs. Among all therapeutic classes, Humira, Eliquis and Revlimid were the top three drugs sold. Among oncologics, the top pharmaceutical sales sector, Revlimid (marketed by Celgene) generated the most revenue in recent years.

Explosive growth in biotechnology in recent years can't be understated. What's fueling this rapid growth varies, as biotech's applications range from healthcare and agriculture to energy. COVID-19 brought more attention to biotechnology, as biotech companies were central to vaccine development and reopening the economy. Biotech's potential to develop vaccines shifted the industry's trajectory, with investment reaching unprecedented levels globally and spurring more start-up activity than ever. Sky-high investment began settling in 2022 as higher interest rates moved risk-averse investors away from the industry. While investor uncertainty is alleviating in 2024, many biotechnology companies will still navigate a challenging funding environment. Globally, rising government investment toward biotechnology, specifically regarding R&D, expedited pathways and innovative therapies, helps offset this impact. In all, revenue has been expanding at a CAGR of 2.4% to an estimated $558.8 billion over the past five years, including expected growth of 2.4% in 2023. Research and development (R&D) is critical for biotechnology companies to successfully discover, develop and commercialize new products. Yet, early-stage biotech can't cover the skyrocketing costs of R&D, relying on outside funding for growth instead. Biotech evaded the economic downturn during COVID-19 as investors poured capital into the field, but investment settled as the pandemic went on the back burner in 2022. While interest rate hikes are settling in influential markets like the US in 2024, economic headwinds in nations like China, regulatory pressures and geopolitical tensions foster an uncertain funding environment. Where the biotechnology industry is headed globally will depend on several factors. Biotechnology's potential to slow climate change, accelerate the energy transition and transform healthcare delivery will encourage more government support nationally, regionally and internationally. Developing a robust bioeconomy will also be a central goal of many developed economies, especially as other countries build momentum. Merger and acquisition activity will accelerate as giant multinational pharma companies lose patents to their blockbuster drugs and acquire promising biotechs to augment their pipelines. Industry-wide revenue will continue expanding, rising at a CAGR of 3.4% to an estimated $659.9 billion over the next five years.

United States US: PFE: Revenue (External): Essential Health Product: US data was reported at 4,859,000.000 USD th in Sep 2018. This records an increase from the previous number of 3,379,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: US data is updated quarterly, averaging 4,849,500.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 9,596,000.000 USD th in Dec 2016 and a record low of 1,731,000.000 USD th in Mar 2018. United States US: PFE: Revenue (External): Essential Health Product: US data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.